Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer Inc. announced today that tofacitinib has been approved for the treatment of rheumatoid arthritis in patients who had an inadequate response to existing therapies in several additional countries around the world, including Switzerland, which is the first European country to receive approval.

15 Jul 2013

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

Study: More people are being affected by drug-induced liver injury than ever before

More people are being affected by drug-induced liver injury (DILI) than ever before, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

27 Jun 2013

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA.

13 Jun 2013

Two studies shed light on joint replacement outcomes in rheumatoid arthritis patients

Two new studies by researchers at Hospital for Special Surgery have shed light on joint replacement outcomes in patients with rheumatoid arthritis. One study overturns the common belief that RA patients have worse outcomes after a total knee replacement than patients who undergo the operation for osteoarthritis. The other study demonstrates that RA patients who undergo a total hip replacement were as likely to have significant improvements in function and pain as patients with osteoarthritis, even though they did not do as well.

12 Jun 2013

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

A new study conducted in an ethnically diverse and predominantly low income population found that only one-fifth of rheumatoid arthritis patients had an overall adherence rate to prescribed oral medications at 80% or greater.

1 Jun 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Study: Biologic response modifying drugs can cause acute liver injury

A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Apr 2013

Crohn’s permanent stoma rates plummet in post-biologic era

Permanent stoma creation in patients with extensive Crohn’s disease has fallen to a third of its previous rate following the advent of biologic therapy, research shows.

25 Apr 2013

LabCorp launches expanded IBD testing profile

Laboratory Corporation of America Holdings announced today the availability of an expanded testing menu to help clinicians diagnose, treat and monitor the course of Inflammatory Bowel Disease.

1 Apr 2013

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Pfizer Inc. announced today that the Japanese Ministry of Health, Labor and Welfare has approved XELJANZ (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis who have had an inadequate response to existing therapies.

25 Mar 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

‘Off the shelf’ stem cells show promise for perianal fistula

Expanded allogenic adipose-derived stem cells are effective for the treatment of perianal fistula in patients with Crohn’s disease, suggest the results of a phase I/II trial.

31 Oct 2012

Carotid ultrasound improves risk management in rheumatoid arthritis

A trial of radiofrequency ultrasound in patients with rheumatoid arthritis has shown that carotid intima-media thickness is significantly greater in patients treated only with synthetic therapeutics compared with those who are also taking biologics.

29 Oct 2012

Ciclosporin no more effective than infliximab in severe UC

Ciclosporin and infliximab have similar efficacy for the treatment of patients with refractory severe ulcerative colitis, show the findings of a multinational trial.

18 Oct 2012

Rheumatoid arthritis treatment foiled by gum disease

Periodontal disease may reduce the efficacy of tumor necrosis factor inhibitor treatment in patients with rheumatoid arthritis, preliminary research suggests.

15 Oct 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

Janssen introduces new online scientific resource for U.S. healthcare professionals

Janssen Scientific Affairs, LLC today announced the launch of JanssenMD, a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. The web-based application is designed for use on desktops, tablets, and smartphones and can be accessed at www.janssenMD.com.

28 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012